Sanofi, Regeneron sock $1B-plus into new meds, Dupixent included by Tracy Staton Monday, January 8, 2018 With PCSK9 cholesterol drug Praluent ramping up more slowly than expected, Sanofi and Regeneron plan a new investment in blockbuster hopeful Dupixent.
Sanofi's Dupixent clears payer hurdles as scripts ramp up by Tracy Staton Monday, July 31, 2017 Could Dupixent end up beating Novartis’ Cosentyx on launch trajectory? The numbers are looking that way so far, a Sanofi executive said Monday.
NICE backflips on Sanofi's Gaucher med Cerdelga by Carly Helfand Thursday, June 1, 2017 Three months ago, England’s cost watchdogs nixed Sanofi's Gaucher treatment Cerdelga. But they're already singing a different tune.
Sanofi Genzyme chief Meeker bows out, Sibold steps in by Tracy Staton Wednesday, April 5, 2017 As Sanofi's Genzyme unit gears up for a blockbuster Dupixent launch, CEO David Meeker is making an exit, with insider Bill Sibold taking his place.
